Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512694 · ClinicalTrials.gov registry record
Duke Lupus Registry
A clinical trial of Systemic Lupus Erythematosus and Cutaneous Lupus, sponsored by Duke University.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT00512694 is a study of Systemic Lupus Erythematosus and Cutaneous Lupus that is actively recruiting participants, run by Duke University. The registered enrollment target is 1,000 participants, above the 370-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (170% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00512694, a study of Systemic Lupus Erythematosus and Cutaneous Lupus, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Lupus is a systemic autoimmune disease that can present with many varied symptoms, including joint pain, fevers, kidney disease, and rashes. Lupus can affect anyone, but it is most common in younger women. The Duke Lupus Registry will collect information and blood samples from patients with lupus (systemic lupus erythematosus or cutaneous lupus) seen in the Duke Rheumatology clinics. The goal of this Registry is to understand how lupus changes over time so that we can improve the treatment of patients with lupus.
Conditions Studied
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2007-07 |
| Est. Completion | 2028-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00512694
The ClinicalTrials.gov registry entry for NCT00512694 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 370-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (170% higher). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 0 interventions.
NCT00512694 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00512694 about?
NCT00512694 is a clinical study titled "Duke Lupus Registry". Lupus is a systemic autoimmune disease that can present with many varied symptoms, including joint pain, fevers, kidney disease, and rashes. Lupus can affect anyone, but it is most common in younger women. The Duke Lupus Registry will collect information and blood samples from patients with lupus (...
What is the current status of trial NCT00512694?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2007-07. Estimated completion is 2028-06.
What conditions does trial NCT00512694 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, Cutaneous Lupus.
Who is sponsoring clinical trial NCT00512694?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00512694 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
RECRUITING
-
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.